GlaxoSmithKline and Theravance have announced that Canadian regulators approved the Anoro Ellipta umeclidinium/vilanterol DPI for the treatment of COPD on December 23, 2013, shortly after the US FDA approved the product. The dosage approved for Canada is 62.5/25mcg.
GSK Canada President Paul Lirette commented, “The market authorization of Anoro Ellipta in Canada provides an important treatment option for appropriate patients with COPD. It is a new once-daily combination product that enables patients to receive two bronchodilators in a single daily inhalation.”
Theravance CEO Rick E. Winningham said, “We are delighted that Anoro Ellipta has achieved market authorization in Canada for the treatment of COPD. This is an important step forward for Theravance and GSK and reinforces our long-standing commitment to work together for patients with respiratory disease.”
Read the GSK/Theravance press release.
